Verition Fund Management
AMLX icon

Verition Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Verition Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,264
Closed -$184K – 2079
2026
Q1 		$184K Sell
13,264
-16,223
-55% -$228K ﹤0.01% 1964
2025
Q4 		$356K Sell
29,487
-34,409
-54% -$467K ﹤0.01% 2902
2025
Q3 		$868K Buy
+63,896
New +$601K ﹤0.01% 2635
2025
Q2 		– Sell
-24,013
Closed -$85K – 3622
2025
Q1 		$85K Buy
+24,013
New +$85.5K ﹤0.01% 3168
2023
Q4 		– Sell
-267,694
Closed -$4.9M – 2310
2023
Q3 		$4.9M Buy
267,694
+46,561
+21% +$985K 0.06% 442
2023
Q2 		$4.77M Sell
221,133
-465
-0.2% -$12.6K 0.06% 380
2023
Q1 		$6.5M Sell
221,598
-38,953
-15% -$1.35M 0.09% 292
2022
Q4 		$9.63M Sell
260,551
-51,865
-17% -$1.84M 0.15% 163
2022
Q3 		$8.79M Sell
312,416
-637,713
-67% -$15.9M 0.1% 245
2022
Q2 		$18.3M Buy
950,129
+24,776
+3% +$294K 0.36% 26
2022
Q1 		$11.9M Buy
+925,353
New +$20.9M 0.14% 121

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Verition Fund Management's AMLX Position: Q2 2026 in Review

Verition Fund Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 13,264 shares — an estimated $184K sold.

Verition Fund Management first reported a position in AMLX in Q1 2022 and held it in 11 quarters. The position peaked at $18.3M in Q2 2022. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Verition Fund Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Verition Fund Management sold 13,264 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $184K.
  • Verition Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Verition Fund Management's Amylyx Pharmaceuticals position peaked at $18.3M in Q2 2022.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.